Case 3: In a PD-L1 Negative Patient, Is There Any Benefit to Using Single Agent IO/Chemotherapy or Dual Agent IO/ Chemotherapy?
Host: Charu Aggarwal, MD, MPH
\n\n Host: Joshua E. Reuss, MD
\n\n\n \n
The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the last few years. This program aims to improve the understanding among oncology clinicians of the application and use of IO to treat patients with advanced or metastatic NSCLC without actionable driver alterations, including guideline recommendations for the duration of therapy and how best to manage special populations, while optimizing care by minimizing immune-related adverse events.